EyePoint Q2 net loss $94.5M ($1.09/sh); cash $180M; LUGANO data expected August 2026

EyePoint, Inc.

Net loss $94.5M vs $59.4M YoY; revenue $0.5M vs $5.3M.
Cash and investments $180M as of June 30, 2026, down from $223M at March 31, 2026.
LUGANO Phase 3 wet AMD topline data expected in August 2026; LUCIA data Q4 2026.
DME Phase 3 trials COMO and CAPRI fully enrolled (over 480 patients); topline data Q4 2027.
Appointed Tarek S. Hassan, M.D., as Chief Strategic Science Officer in July 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.